Background: Schizophrenia is a chronic, severe psychotic disease with high incidence. Treatment of schizophrenia with neuroleptic is a major medical advance, but sometime its result is still limited. Objective: To study the effect of electroconvulsive therapy (EC) in treatment of paranoid schizophrenic patients. Subject and methods: 101 paranoid schizophrenic patients treated by neuroleptic alone or neuroleptic combined EC, were treated in the Mental Department of Hospital 103 and Nam Dinh Mental Hospital from May, 2006 to June, 2007. Results and Conclusion: All 100% of the patients had a positive response to EC; the mean times of EC were 7.63\xb11.4 times for one. The regression of hallucination was observed after 4.6\xb11.49 times of EC; delusion after 4.96\xb11.4 times; suicide attempt after 3.25\xb10.96 times and refusing to eat after 4.96\xb12.1 times of EC; insomnia disappeared after 4.96\xb12.1 times of EC. Some side effects of the EC therapy: 100% of patients had orientation disorder; headache with light and moderate level accounted for 69.65% and 26.79%, respectively. Combination therapy made patients more stable, compared to neuroleptic therapy alone (p<0.05).
paranoid schizophrenia ; electroconvulsive therapy

60 patients with schizophrenia type paranoid treated in the Central hospital of Psychology were randomly divided into 2 groups: group I (30 patients): intensive intervention; group II (30 patient): control. The results have shown that the ages which starts suffering the disease were about 20-35; after 4 months of research on progress of the schizophrenia type paranoid and after chomotherapy and training for family in the publicity, the correct awareness, attitude for disease and ability of the social reintegration in the intervented group were better than these in the control
Schizophrenia, Paranoid ; Drug therapy

Patients were divided into 2 groups, one involved 30 patients who have recurrence within 10 years, and the other involved 20 patients without recurrence. All patients were diagnosed with schizophrenia type paranoid using ICD-10 criteria. The result showed that to lower the recurrence of schizophrenia patients, the education and communication measures are needed in the first place so that the patients’ family accept and tolerate them. Try to limit adverse effects such as psychological trauma and stress. Especially, the medical intervention is very important soon after this detecting this condition
Schizophrenia, Paranoid ; Recurrence

Clozapine is a gold standard medication and drug of choice in refractory schizophrenia. Among many of its fatal side effects, delirium is less reported and inconsistently recognized by clinicians. We here present a case of delirium which emerged during retreatment with clozapine in a patient of paranoid schizophrenia. A patient diagnosed with paranoid schizophrenia, was restarted on clozapine after he left medications and became symptomatic. He was delirious on 22nd day after clozapine was restarted. Clozapine was stopped and the patient was managed with standard treatment for delirium. After one week interval, clozapine was restarted. Delirium was not noted till 6 weeks of his hospital stay. Clozapine induced central anticholinergic toxicity or clozapine induced seizure might cause delirium in index case. Limited literature exist delirium with clozapine. Clinicians must have high index of suspicion to detect delirium during clozapine therapy. More researches should focus to explore the association between delirium and clozapine.
Clozapine* ; Delirium* ; Humans ; Length of Stay ; Retreatment ; Risk Factors ; Schizophrenia ; Schizophrenia, Paranoid ; Seizures

The purposes of this study were to test the negative association between schizophrenia and rheumatoid arthritis(RA) and to clarify the role of prolactin and estrogen as protective factors in this association. The author compared the prevalence rate of RA between 561 patients with schizophrenia and 222 patients with mood disorder. For investigating the role of estrogen and prolactin, the author checked the plasma prolactin and estradiol level in 80 patients with paranoid schizophrenia and 77 patients with RA. The results were as follows. 1) Epidemiological data The prevalence rate of RA in the schizophrenic group was 0/561 and that of RA in the mood disorder group was 2/222. To compare these results between two groups, the author applied the Binomial test using the average prevalence rate of RA(0.8%) in the general population as a reference rate. The prevalence rate of RA in the schizophrenic group was significantly lower than that of RA in the general population. However, the prevalence rate of RA in the mood disorder group was not significantly different to that of RA in the general population. 2) Comparison of plasma prolactin and estradiol level between two groups. The plasma level of prolactin in the schizophrenic group was significantly higher than that of prolactin in th RA group(p=0.000). However, the plasma level of estradiol in the schizophrenic group was significantly lower than that of estradiol in the RA group(p=0.017). These results were not consistent across gender. To contrast with the results in the female group, which were consistent with the results in the total subjects, for the male group, the plasma levels of prolactin and estradiol in the schizophrenic group were significantly higher than those of prolactin and estradiol in th RA group. These results support the results of previous studies which confirm the negative association between schizophrenia and RA. These results also suggest that the elevation of plasma prolactin level in the patient with schizophrenia has a antirheumatic effect while the elevation of plasma estradiol level in the patients with RA has a anti-schizophrenic effect, and that these effects act as a possible mechanism in the negative association between two disorders. However, these results suggest that this association is specific to female patients.
Arthritis, Rheumatoid* ; Epidemiology* ; Estradiol ; Estrogens* ; Female ; Humans ; Male ; Mood Disorders ; Plasma ; Prevalence ; Prolactin* ; Schizophrenia* ; Schizophrenia, Paranoid

Conventional neuroleptic treatment of organic delusional disorder can induce many serious side effects including extrapyramidal symptoms, sedation and tardive dyskinesia, especially in elderly patients. Risperidone is an atypical neuroleptics that is lack of severe extrapyramidal symptoms. This 68-year-old male case demonstrated that elderly patients with organic delusional disorder could be treated with risperidone without serious side effects.
Aged* ; Antipsychotic Agents ; Delusions* ; Humans ; Male ; Movement Disorders ; Risperidone* ; Schizophrenia, Paranoid*

OBJECTIVES: Some emotional components, such as self-esteem, depression and anxiety, have been reported to be associated with paranoia in non-clinical population and schizophrenia patients. The aim of this study was to investigate the correlation between self-esteem and paranoia in healthy controls, in ultra-high risk for psychosis and schizophrenia patients. METHODS: 34 subjects with recent onset schizophrenia, 36 subjects with ultra-high risk for psychosis, and 44 healthy volunteers participated in this study. A detailed assessment was made of the paranoia, self-esteem, depression, and anxiety. RESULTS: In all three groups, there were a negative correlation between paranoia and self-esteem, and positive correlations between paranoia and depression and anxiety. In healthy control, lower self-esteem showed a trend to predict higher paranoia, and in ultra-high risk for psychosis, this trend tern on statistically significant level, and in recent onset schizophrenia group, this correlation was disappeared. CONCLUSION: The individual who have lower self-esteem showed higher paranoia tendency under delusional level, but after formation of persecutory delusion, the tendency was disappeared. This result supports the hypothesis that persecutory delusions are a defense against negative affective process.
Animals ; Anxiety ; Charadriiformes ; Delusions ; Depression ; Healthy Volunteers ; Humans ; Paranoid Disorders* ; Psychotic Disorders* ; Schizophrenia*

OBJECTIVES: Patients with schizophrenia often present idea of reference in social situations, but there has been a limitation in quantitatively measuring their reactions to the social stimuli. The aim of this study was to investigate behavioral characteristics of patients with schizophrenia in social situations in which idea of reference can be provoked. METHODS: Forty subjects with schizophrenia (21 males) and 26 healthy volunteers (17 males) performed the idea-of-reference-provoking task, which was composed of movie clips with scenes of two women sitting on a bench of 1 or 5 m away. The conditions consisted of "referential conversation", "non-referential conversation" or "no conversation". The reactions of the participants were rated by the questionnaires for self-referential perception, malevolent interpretation and anxiety reaction. RESULTS: There were significant group differences in the reactions on self-referential perception, malevolent interpretation and anxiety reaction. After the treatment, patients with schizophrenia showed improved scores of the reactions. In particular, score changes of malevolent interpretation and anxiety reaction in patients with schizophrenia were correlated with change of paranoia scale (rs=0.65, p<0.05 and rs =0.73, p<0.05, respectively). CONCLUSION: Patients with schizophrenia revealed self-referential bias and paranoid responses to social situations, which were improved after psychiatric treatment. Self-referential perceptions and paranoid responses may be state dependent rather than trait of schizophrenia.
Anxiety ; Bias (Epidemiology) ; Female ; Healthy Volunteers ; Humans ; Paranoid Disorders ; Surveys and Questionnaires ; Schizophrenia* ; Social Perception*

We experienced clinical improvement by clozapine(mean maintenance dosage: 100mg/day) and antiparkinsonian medication in 68-year-old man, diagnosed both secondary parkinsonism and delusional disorder. This result supports previous reports that clozapine may effectively treat parkinsonism with psychosis.
Aged ; Clozapine* ; Delusions* ; Humans ; Parkinson Disease, Secondary ; Parkinsonian Disorders* ; Psychotic Disorders ; Schizophrenia, Paranoid*

Peripheral edema is observed as an adverse effect of the usage of antipsychotics in the literature. This case report describes a 36-year-old female patient with the diagnosis of paranoid schizophrenia who presented with pretibial edema following initiation of long-acting injectable paliperidone palmitate. Pretibial edema developed within the second week of treatment and completely disappeared after its discontinuation.
Adult ; Antipsychotic Agents ; Diagnosis ; Edema* ; Female ; Humans ; Paliperidone Palmitate* ; Schizophrenia, Paranoid